The DIDB Concomitant Meds Navigator was updated in July and is now available in the Tools section.
This update includes a comprehensive review of OAT1 and OAT3 substrate data. As a result, 61 such characteristics involving 37 compounds were added or updated. For OAT1/3 substrates with supporting clinical data showing an AUCR < 2, the potential clinical significance was further evaluated, and relevant conclusions have been included in the “Characteristic comments” column when available.
Overall, this update adds or revises 100 drug interaction characteristics involving 59 compounds. These include:
- Substrates of CYP2C9, CYP2C19, CYP3A, UGT, P-gp, OAT1, OAT3, OATP1B1, and OATP1B3 (n = 79)
- Inhibitors of CYP2B6, CYP2C8, CYP2C19, CYP3A, UGT1A9, and BCRP (n = 13)
- Inducers of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A (n = 8)
Four drugs were identified as sensitive substrates, all for CYP3A, based on clinical DDI studies or PBPK modeling and simulations using the strong CYP3A inhibitors itraconazole and ketoconazole. No compounds were identified as strong inhibitors or strong inducers in this update.
Additionally, a new “Date added” column has been introduced to the table. This feature allows you to easily filter and identify recently added or updated entries.
Visit the DIDB Concomitant Meds Navigator to explore the complete list of compounds, supporting study details, and additional pharmacokinetic information.
As always, feel free to contact us if you have any questions or comments.